Program overview

The seminar aims to provide an understanding of Health Technology Assessment (HTA) and how it can be utilized in various areas. Hepatitis C is used as an example, not just of HTA but also to illustrate issues related to access to medicines globally.

HTA is an evidence-based, multidisciplinary process intended to support healthcare decision making by assessing properties and effects of one or more new or existing health technologies in comparison with a current standard. It can also provide input into policymaking. Aiming at determining added value, HTA uses explicit analytical frameworks based on research and the scientific method in a systematic, transparent, unbiased way.

This seminar will cover the basics of HTA, elaborating on what it is, the areas that are usually focused on, and the work process involved. This will be followed by a historical overview, indicating how from the Office of Technology Assessment in the US, it has been adopted all over the world. Following the global overview, an account will be provided of the beginnings of HTA in Malaysia and the successes that it has had. Examples will then be provided of how HTA has been used all over the world in policy formulation and decision making including purchasing decisions, determination of benefits packages in healthcare financing and the like.

The second part of the seminar delves further into illustrating the problems with Hepatitis C treatment. There will be an introduction to intellectual property and drugs, patents and monopoly pricing, and the World Trade Organization. AIDS/HIV and Hepatitis C will be used to illustrate the problems, the consequences, and how the problems were eventually overcome in some countries. The work of Malaysian research in the development of Ravidasvir, an affordable antiviral for the treatment of Hepatitis C, that is currently undergoing Phase III trials in Thailand and Malaysia, will be described along with role of Drugs for Neglected Diseases Initiative. The final session for the afternoon will be a description of the experience of the Third World Network in its efforts towards compulsory licensing for Sofosbuvir, a drug for treating Hepatitis C. There will again be a panel discussion on areas related to the topics covered.

Who should attend?

Medical and surgical specialists, pharmacists, general practitioners, medical and health officers, policy makers, and other healthcare professionals.

This seminar has been approved for 8 MMA-CPD points.

Conference website

Please visit the following webpage for online registration, E-brochure and more details and latest updates:

monash.edu.my/jcsmhs/events/eia2018

Registration fee

RM 250 (per person, inclusive of lunch and tea breaks)

Payment

1) Bank Transfer / Direct Bank in
   Payee Name: Monash University Malaysia Sdn Bhd
   Bank Name: Public Bank Berhad
   Account No.: 307 412 960 5

2) Credit Card
   http://finapps.monash.edu.my/ebpg/online_payment.php

Please REGISTER ONLINE and email the payment slip to Ms. Camelia at camelia.marsha@monash.edu

Contacts

For further information, please contact:
Associate Professor Sivalal Sadasivan
E: sivalal@monash.edu / T:03-5514 6315

Ms. Gurmeet Kaur
E: gurmeet.kaur@monash.edu / T: 03-5514 5646
# Program

**Date:** 1 October 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Presenter/Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00 - 8.30 am</td>
<td>REGISTRATION</td>
<td></td>
</tr>
<tr>
<td>8.30 - 8.45 am</td>
<td>Welcome</td>
<td>Prof Andrew Walker, President &amp; Pro-Vice Chancellor, Monash University Malaysia</td>
</tr>
<tr>
<td>8.45 - 9.00 am</td>
<td>Opening Remarks</td>
<td>Prof Mohamed Shajahan Yasin, Head, Jeffrey Cheah School of Medicine &amp; Health Sciences</td>
</tr>
<tr>
<td>9.00 - 9.30 am</td>
<td>Health Technology Assessment (HTA) - Introduction</td>
<td>A/P Sivalal Sadasivan</td>
</tr>
<tr>
<td>9.30 - 10.00 am</td>
<td>HTA - a global overview</td>
<td>Prof David Banta</td>
</tr>
<tr>
<td>10.00 - 10.30 am</td>
<td>Tea Break</td>
<td></td>
</tr>
<tr>
<td>10.30 - 11.00 am</td>
<td>HTA in Malaysia</td>
<td>Dr Junainah Sabirin</td>
</tr>
<tr>
<td>11.00 - 11.30 am</td>
<td>Application of HTA</td>
<td>A/P Sivalal Sadasivan</td>
</tr>
<tr>
<td>11.30 - 12.00 pm</td>
<td>Case Studies of HTA</td>
<td>Prof David Banta</td>
</tr>
<tr>
<td>12.00 - 1.00 pm</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>1.00 - 2.00 pm</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>2.00 - 2.30 pm</td>
<td>Access to Medicines</td>
<td>Dr Ellen T’hoen</td>
</tr>
<tr>
<td>2.30 - 3.00 pm</td>
<td>Hepatitis C in Malaysia</td>
<td>Ms Chee Yoke Ling</td>
</tr>
<tr>
<td>3.00 - 3.30 pm</td>
<td>Affordable Treatment for Hepatitis C</td>
<td>Mr Jean-Michel Piedagnel</td>
</tr>
<tr>
<td>3.30 - 4.30 pm</td>
<td>Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>
Professor Dr David Banta

David Banta, often referred to as the “Father of HTA”, received his MD degree from Duke University and MPH and MS degrees from Harvard University School of Public Health. In 1975 he joined the U.S. Congressional Office of Technology Assessment, where he headed a team that laid out the basic definitions and principles of the then-new field of health technology assessment (HTA). In 1983 he began a long-term relationship with the World Health Organization (WHO), working on the staff in Washington and Copenhagen, and later consulting with WHO staff and traveling to different countries under WHO auspices. During these years, he developed a strong interest in HTA in developing countries. In 1993, he joined the Netherlands Applied Research Organization (TNO), where he worked on issues related to HTA in the Netherlands, in Europe, and in many countries around the world. At the same time, he is Professor Emeritus at Maastricht University, where he taught HTA and supervised several doctoral candidates. He has consulted many times with the World Bank, working on HTA in China and Malaysia, and in a number of Eastern European countries. He has also often been a consultant to national and regional governments or their HTA programs. He has published extensively on issues related to HTA and policies toward health technology.

Dr Ellen FM 't Hoen

Ellen ‘t Hoen is a lawyer and public health advocate with over 30 years of experience working on pharmaceutical and intellectual property policies. She works as an independent consultant in medicines law and policy for a number of international organisations and governments and is a researcher at the Global Health Unit of the University Medical Center Groningen, The Netherlands. From 1999 until 2009 she was the Director of Policy and Advocacy at Médecins sans Frontières’ (MSF) Campaign for Access to Essential Medicines. In 2009 she joined UNITAID to set up the Medicines Patent Pool (MPP), an initiative that negotiates patent licenses to ensure access to affordable generic medicines. She was the MPP’s first executive director until 2012. She is a member of the Lancet Commission on Essential Medicines Policies, the Advisory Board of Universities Allied for Essential Medicines (UAEM) and the Editorial Board of the Journal of Public Health Policy. In 2005, 2006, 2010 and 2011 she was listed as one of the 50 most influential people in intellectual property by the journal Managing Intellectual Property. She has published widely and is the author of several books. In 2017 she received the Prix Prescrire for her latest book “Private Patents and Public Health: Changing intellectual property rules for public health.”

Associate Professor Sivalal Sadasivan

Dr Sivalal Sadasivan is currently an Associate Professor at Jeffrey Cheah School of Medicine & Health Sciences, Monash University Malaysia, having joined the University in 2006. Dr Sivalal was previously the Head of the Health Technology Assessment Unit, and a Deputy Director of the Medical Development Division, Ministry of Health, Malaysia. He was also Director of the WHO Collaborating Centre for Evidence Based Practice in Health Care. Apart from managing the Health Technology Assessment programme in Ministry of Health Malaysia, he was also involved clinical practice guidelines, medical device regulation, hospital management, health care financing, and Quality Assurance. He has been a consultant on health technology assessment in Turkey, Pakistan, Indonesia, and Iran, and a consultant with the World Health Organization on assisting Sudan with developing a national health technology policy, and later in setting up a system of medical device regulation.

In addition, he has presented innumerable papers at national and international conferences both locally and abroad, has had publications in numerous journals, and is an editor and reviewer for a number of international journals.

Dr Junainah Sabirin

Dr Junainah Sabirin is a Public Health Physician, who graduated from University of Malaya, Malaysia (MBBS and MPH). She heads the Malaysian Health Technology Assessment Section (MaHTAS), as a Deputy Director of Medical Development Division, Ministry of Health, Malaysia. She has been working in MaHTAS for the last 10 years and has been involved in conducting health technology assessment especially for facilities under the Ministry of Health, Malaysia. She is currently responsible for the implementation HTA activities including local economic evaluation, Horizon Scanning activities, Evidence-based Clinical Practice Guidelines development and implementation, Value Based Medicine and related training. Dr Junainah has previously worked in hospitals, district health offices and at the Disease Control Division, Ministry of Health, Malaysia.

Mr Jean-Michel Piedagnel

Jean-Michel Piedagnel graduated from École de Commerce (ESCE), an international business school in Paris. He started his career working for the world’s largest sailing boat manufacturer in sales, marketing and export manager in France. In 1995, he joined Médecins Sans Frontières to run some of their most challenging relief projects, in DRC, Goma, Burundi, Nigeria, Kosovo, Lebanon, Sierra Leone, Angola and Pakistan. After working in the headquarters in Paris, he moved to London as the Executive Director for seven years and oversaw a period of unprecedented growth and enhanced reputation for MSF in the UK. Under his leadership, MSF UK was voted to be the most Admired British Charity in 2004 and 2005. He joined Drugs for Neglected Diseases Initiative (DNDi) as Head of the South-East Asia office, in April 2016.

Ms Chee Yoke Ling

Ms Chee Yoke Ling is an international lawyer whose areas of expertise include the environmental, social and economic impacts of globalization, especially in countries of the South. Since 1993 she has worked closely with key negotiators from the global South, scientists and NGOs to campaign for bio safety and climate justice. She was a member of a Malaysian task force that worked on two national laws related to bio safety and the regulation of access to genetic resources. Her current focus areas are: climate change, the interface between biodiversity/traditional knowledge and intellectual property rights, the relationship between multilateral environmental agreements and trade agreements, environmentally-sound technology transfer, and developments on these issues at the UN Framework Convention on Climate Change, Convention on Biological Diversity, World Trade Organisation, and the World Intellectual Property Organisation. She is a Director of Third World Network, a non-profit international policy research and advocacy organization involved in sustainable development issues. She is trained in international law, with degrees from the University of Malaya (Malaysia) and Cambridge University (UK).